Trametinib (Mekinist) — MEK Inhibitor for BRAF V600-Mutated Cancer
July 17, 2026
Trametinib inhibits MEK1/2 in the MAPK pathway, effective in melanoma and lung cancer with BRAF V600 mutations. Usually combined with Dabrafenib.
Targeting the MAPK/MEK Pathway
Trametinib (Mekinist) is a selective MEK1/2 inhibitor acting on the MAPK/ERK signalling pathway, which is frequently over-activated in cancers harbouring BRAF V600E/K mutations. Combining Trametinib + Dabrafenib (BRAF inhibitor) creates dual blockade, overcoming the resistance mechanisms seen with single BRAF inhibitor therapy.
Indications
Advanced melanoma with BRAF V600 mutation (Dabrafenib + Trametinib combination is standard of care). BRAF V600E non-small cell lung cancer. Anaplastic thyroid cancer BRAF V600E (combined with Dabrafenib).
In China
BRAF V600 testing is mandatory in melanoma diagnostic workflows in China. The Dabrafenib + Trametinib protocol is applied at HYGEIA and GoBroad. Patients require BRAF mutation testing before this protocol is considered.
Disclaimer
Information is for reference only. Genetic testing and protocols are determined by the oncologist.
Related Images
